China Universal Asset Management Co. Ltd. Has $2.16 Million Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

China Universal Asset Management Co. Ltd. boosted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 23.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,428 shares of the company’s stock after acquiring an additional 4,962 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Vaxcyte were worth $2,163,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of PCVX. Riverview Trust Co acquired a new stake in shares of Vaxcyte in the 3rd quarter valued at $27,000. Blue Trust Inc. boosted its position in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after buying an additional 93 shares in the last quarter. Meeder Asset Management Inc. boosted its position in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after buying an additional 635 shares in the last quarter. Nomura Asset Management Co. Ltd. bought a new stake in Vaxcyte during the third quarter worth about $92,000. Finally, Signaturefd LLC increased its holdings in shares of Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock worth $120,000 after buying an additional 358 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Vaxcyte

In other news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the completion of the transaction, the chief executive officer now directly owns 450,301 shares in the company, valued at approximately $41,630,327.45. The trade was a 3.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $92.49, for a total transaction of $739,920.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares in the company, valued at $19,024,730.55. This represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,982 shares of company stock worth $5,651,725. 3.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PCVX shares. The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte presently has an average rating of “Buy” and an average target price of $145.71.

Vaxcyte Trading Down 3.9 %

Shares of NASDAQ PCVX opened at $88.32 on Friday. The firm’s 50-day moving average is $87.60 and its 200-day moving average is $94.21. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The firm has a market capitalization of $11.01 billion, a PE ratio of -19.20 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the business posted ($0.91) EPS. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.